298 related articles for article (PubMed ID: 32503344)
21. Effects of Alemtuzumab on (Auto)antigen-Specific Immune Responses.
Hilger C; Riedhammer C; Orsó E; Weissert R
Front Immunol; 2020; 11():563645. PubMed ID: 33133074
[TBL] [Abstract][Full Text] [Related]
22. Immune reconstitution therapy (IRT) in multiple sclerosis: the rationale.
Karussis D; Petrou P
Immunol Res; 2018 Dec; 66(6):642-648. PubMed ID: 30443887
[TBL] [Abstract][Full Text] [Related]
23. Impact of alemtuzumab treatment on the survival and function of human regulatory T cells in vitro.
Havari E; Turner MJ; Campos-Rivera J; Shankara S; Nguyen TH; Roberts B; Siders W; Kaplan JM
Immunology; 2014 Jan; 141(1):123-31. PubMed ID: 24116901
[TBL] [Abstract][Full Text] [Related]
24. Long-Term Effects of Alemtuzumab on CD4+ Lymphocytes in Multiple Sclerosis Patients: A 72-Month Follow-Up.
Rolla S; De Mercanti SF; Bardina V; Maglione A; Taverna D; Novelli F; Cocco E; Vladic A; Habek M; Adamec I; Annovazzi POL; Horakova D; Clerico M
Front Immunol; 2022; 13():818325. PubMed ID: 35296069
[TBL] [Abstract][Full Text] [Related]
25. Alemtuzumab in Multiple Sclerosis: Short- and Long-Term Effects of Immunodepletion on the Peripheral Treg Compartment.
Haas J; Würthwein C; Korporal-Kuhnke M; Viehoever A; Jarius S; Ruck T; Pfeuffer S; Meuth SG; Wildemann B
Front Immunol; 2019; 10():1204. PubMed ID: 31214176
[TBL] [Abstract][Full Text] [Related]
26. Marked neutropenia: Significant but rare in people with multiple sclerosis after alemtuzumab treatment.
Baker D; Giovannoni G; Schmierer K
Mult Scler Relat Disord; 2017 Nov; 18():181-183. PubMed ID: 29141806
[TBL] [Abstract][Full Text] [Related]
27. Multiple sclerosis: reprogramming the immune repertoire with alemtuzumab in MS.
Wiendl H; Kieseier B
Nat Rev Neurol; 2013 Mar; 9(3):125-6. PubMed ID: 23358486
[TBL] [Abstract][Full Text] [Related]
28. Immune Regulatory Cell Bias Following Alemtuzumab Treatment in Relapsing-Remitting Multiple Sclerosis.
Kashani N; Kelland EE; Vajdi B; Anderson LM; Gilmore W; Lund BT
Front Immunol; 2021; 12():706278. PubMed ID: 34777337
[TBL] [Abstract][Full Text] [Related]
29. Immediate transient thrombocytopenia at the time of alemtuzumab infusion in multiple sclerosis.
Ranganathan U; Kaunzner U; Foster S; Vartanian T; Perumal JS
Mult Scler; 2018 Apr; 24(4):540-542. PubMed ID: 28287030
[TBL] [Abstract][Full Text] [Related]
30. Immune Reconstitution and Infection Patterns after Early Alemtuzumab and Reduced Intensity Transplantation for Nonmalignant Disorders in Pediatric Patients.
Bhatt ST; Bednarski JJ; Berg J; Trinkaus K; Murray L; Hayashi R; Schulz G; Hente M; Grimley M; Chan KW; Kamani N; Jacobsohn D; Nieder M; Hale G; Yu L; Adams R; Dalal J; Pulsipher MA; Haut P; Chaudhury S; Davis J; Jaroscak J; Andreansky M; Willert J; Shenoy S
Biol Blood Marrow Transplant; 2019 Mar; 25(3):556-561. PubMed ID: 30321596
[TBL] [Abstract][Full Text] [Related]
31. Alemtuzumab therapy for multiple sclerosis.
Coles AJ
Neurotherapeutics; 2013 Jan; 10(1):29-33. PubMed ID: 23184314
[TBL] [Abstract][Full Text] [Related]
32. [ALEMTUZUMAB: BENEFITS AND CHALLENGES OF A NEW THERAPY IN MULTIPLE SCLEROSIS].
Illés Z; Sejbaek T; Csépány T
Ideggyogy Sz; 2015 May; 68(5-6):155-64. PubMed ID: 26182606
[TBL] [Abstract][Full Text] [Related]
33. COVID-19 in a multiple sclerosis (MS) patient treated with alemtuzumab: Insight to the immune response after COVID.
Fiorella C; Lorna G
Mult Scler Relat Disord; 2020 Nov; 46():102447. PubMed ID: 32835901
[TBL] [Abstract][Full Text] [Related]
34. A cell-based assay for the detection of neutralizing antibodies against alemtuzumab.
Ali L; Saxena G; Jones M; Leisegang GR; Gammon L; Gnanapavan S; Giovannoni G; Schmierer K; Baker D; Kang AS
Biotechniques; 2020 Apr; 68(4):185-190. PubMed ID: 32096651
[No Abstract] [Full Text] [Related]
35. Alemtuzumab for the treatment of multiple sclerosis.
Evan JR; Bozkurt SB; Thomas NC; Bagnato F
Expert Opin Biol Ther; 2018 Mar; 18(3):323-334. PubMed ID: 29309202
[TBL] [Abstract][Full Text] [Related]
36. Acute leukocytosis during alemtuzumab treatment in patients with active relapsing-remitting multiple sclerosis.
Iovino A; Aruta F; Carotenuto A; Manganelli F; Iodice R
Mult Scler Relat Disord; 2019 Feb; 28():98-100. PubMed ID: 30580038
[TBL] [Abstract][Full Text] [Related]
37. Mode of action and clinical studies with alemtuzumab.
Jones JL; Coles AJ
Exp Neurol; 2014 Dec; 262 Pt A():37-43. PubMed ID: 24792641
[TBL] [Abstract][Full Text] [Related]
38. Antibody-mediated cell depletion therapies in multiple sclerosis.
Mariottini A; Muraro PA; Lünemann JD
Front Immunol; 2022; 13():953649. PubMed ID: 36172350
[TBL] [Abstract][Full Text] [Related]
39. Severe B cell-mediated disease activation despite two cycles of alemtuzumab in a patient with multiple sclerosis.
Hyun JW; Kim Y; Kim G; Kim SH; Kim HJ
Mult Scler; 2019 Dec; 25(14):1942-1945. PubMed ID: 30403365
[TBL] [Abstract][Full Text] [Related]
40. Autoimmune Thyroid Diseases in Patients Treated with Alemtuzumab for Multiple Sclerosis: An Example of Selective Anti-TSH-Receptor Immune Response.
Rotondi M; Molteni M; Leporati P; Capelli V; Marinò M; Chiovato L
Front Endocrinol (Lausanne); 2017; 8():254. PubMed ID: 29033895
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]